Research programme: second generation farnesyl transferase inhibitors - Bristol-Myers Squibb
Alternative Names: BMS-316810; Second generation farnesyl transferase inhibitors research programmeLatest Information Update: 20 Mar 2007
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 24 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)